Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19

Yahya Shaikh, MD, MPH^{*1} and Ishaan Gupta, MBBS^{*2}, Sophia Purekal, MD³, Mary Jane E. Vaeth, BS³, Maisha Foyez, GED³, Charles D. Callahan, DO⁴, Maryam Elhabashy, BA⁵, James R. Ficke, MD⁶, Albert W. Wu, MD, MPH⁷, Paul G. Auwaerter, MD, MBA⁸, Melinda E. Kantsiper, MD², Zishan K. Siddiqui, MD, MBA⁹

*These authors contributed equally

- 1. MITRE Corporation, Baltimore, Maryland, USA
- Division of Hospital Medicine, Johns Hopkins Bayview Medical Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- 3. Baltimore Convention Center Field Hospital, Baltimore, Maryland, USA
- Department of Population Health, University of Maryland Medical Center, Baltimore, Maryland, USA
- 5. University of Maryland, Baltimore County, Maryland, USA
- Department of Orthopaedic Surgery, Johns Hopkins University, Baltimore, Maryland, USA
- Department of Medicine, General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

- 8. The Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
- 9. Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA

Running title: Racial Disparities in COVID-19 mAb use

Abstract word count: 97 words

Manuscript word count: 1159 words

Corresponding author:

Ishaan Gupta MD

Johns Hopkins Bayview Medical Center

5200 Eastern Avenue

MFL East Tower, Room 260

Baltimore MD 21224

Phone: 410-550-5018

Fax No:

Email: igupta4@jhmi.edu

Abstract

Background and Methods: We conducted a single center cross-sectional study to investigate racial disparities in the hesitancy and utilization of monoclonal antibody (mAb) treatment of COVID-19 among treatment eligible patients who were referred to the infusion center between January 4, 2021 and May 14, 2021.

Results: Among the 2,406 eligible participants, African Americans were significantly more likely to underutilize mAb treatment (OR 1.8; 95% CI 1.5-2.1) and miss treatment opportunities due to monoclonal hesitancy (OR 1.7, 95% CI 1.3-2.1).

Conclusion: Addressing racial disparities in mAb delivery is an opportunity to bridge the racial inequities in COVID-19 care.

Keywords: Disparities, Utilization, Equity, Monoclonal Antibody, Hesitancy, COVID-19

1 Background

2	Since the start of the COVID-19 pandemic, members of racial and ethnic minorities
3	have borne a disproportionate burden of disease with disparities in infection rates,
4	hospitalization, and death. ^{1,2} Further, differences have also been seen in preventive
5	measures, with African-Americans expressing a rate of vaccine hesitancy three times
6	greater than whites. ³ Targeted interventions to address barriers and improve equity in
7	COVID-19 outcomes have included uptake of vaccines. ^{4,5} However, whether access to
8	highly effective monoclonal antibody (mAb) infusions for the treatment of COVID-19
9	face similar issues is unknown.
10	Three anti-SARS-CoV-2 monoclonal antibody products have received Emergency Use
11	Authorizations (EUAs) from the Food and Drug Administration (FDA) to treat mild to
12	moderate COVID-19 in non-hospitalized patients at high risk for progressing to severe
13	disease and/or hospitalization. These have been shown to improve outcomes. ⁶ We
14	investigated if there is evidence for racial disparities in utilization of mAb and treatment
15	hesitancy after referral to a high-volume infusion site.

16

17 Methods

18 This was a cross-sectional analysis of patients seen at the mAb infusion site linked to 19 the Baltimore Convention Center Field Hospital (BCCFH), Maryland's largest infusion 20 site. The operational structure for BCCFH has been described.⁷ All patients referred to 21 the center from January 4th, 2021 to May 14th, 2021, who were eligible to receive mAb

treatment based on their disease severity and risk factors, were included in the study. 22 23 Patients were referred by community providers using a web-based form that 24 automatically populated the scheduling spreadsheet. Treatment was provided with no 25 out-of-pocket payment irrespective of insurance status. Free transportation was offered 26 to and from the infusion center. Patients outside of the 10-day eligibility period were 27 excluded and marked as "Timed Out." Attempts were made to contact eligible patients 28 within 24 hours to schedule a treatment. Additional attempts were made, and the 29 referring provider was contacted via automated email after two failed attempts. The 30 disposition status of the patient was documented after each contact attempt (e.g., 31 "Unable to be Reached," "Declined," "Cancelled," "Hospitalized," "Treated Elsewhere," 32 "Scheduled"). The scheduled patient's status was updated on the planned infusion date 33 ("No-Show," "ED-transfer after Arrival," "Treated"). Final disposition status of "Refused 34 Treatment" or "Cancelled" was categorized as mAb hesitancy partly because further 35 inquiry often revealed doubts about the treatment. Treatment at BCCFH or elsewhere 36 was categorized "Appropriate Utilization." All other disposition statuses of referred patients and eligible patients that did not lead to treatment were considered 37 "Underutilization." 38

39 Racial disparities were assessed using logistic regression models to compare odds by 40 race for treatment utilization, final disposition status, overall underutilization, and 41 disposition consistent with mAb hesitancy. All analyses were conducted as both 42 unadjusted models and models adjusted for gender, age, and poverty rate using the 43 patient's zip code of residence as a surrogate for socioeconomic status derived from the 44 American Community Survey.⁸ All statistical testing was 2-tailed with an $\alpha \equiv 0.05$ using

2

SAS Studio Software, Version 3.8 of SAS (SAS Institute Inc., Cary, NC, USA). The
study was approved by local institutional review board. The dataset is not publicly
available.

48 **Results**

49 Between 1/04/2021 and 05/14/2021, 2406 eligible patients were referred, of which 50 57.4% (1382) were white, 35% (841) were African American, 3.4% were Latinx, 3.1% 51 Asian, with Native Americans, Pacific Islanders, and self-identified categories making up 52 less than 1%. African American patients were younger, with a mean age of 54.6 (95%) 53 CI, 53.6-55.6) vs. 61.3 years (95% CI, 60.5-62.1) for whites, and were more often from 54 neighborhoods with higher levels of poverty (Table 1). Overall, 69.5% (95% CI, 67.6-55 71.3) of referred patients were treated at BCCFH, with a greater proportion of whites 56 receiving mAb (74% [95% CI, 71.7-76.3]) vs African American (63.8% [95% CI, 60.5-67.0]). 57

Among referred patients, 12.6% (95% CI, 10.3-14.8) of African Americans and 8.0%
(95% CI, 6.5-9.4) of whites refused treatment; and 8.7% (95% CI, 6.8-10.6) of African
Americans and 4.5% of whites (95% CI, 3.4-5.6) were unreachable. (Figure 1) Overall,
mAb hesitancy accounted for 48.0% (95% CI, 44.3-51.7) of underutilization.

Compared to whites, African-Americans had 3.5 (95% CI, 1.4-8.8) times greater odds of
being transferred to the Emergency Department on arrival to infusion site; 2.0 times
greater odds (95% CI, 1.4-2.9) of being unreachable during the 10-day eligibility window
for mAb treatment; and 1.7 times greater odds (95% CI, 1.3-2.2) of refusing treatment.

African Americans had greater odds of under-utilizing mAb infusion treatment (1.8; 95%
CI: 1.5, 2.1) and missing treatment opportunities because of monoclonal hesitancy (1.7;
95% CI: 1.3-2.1). Whites had greater odds of being treated at BCCFH (OR 1.6; 95% CI,
1.3-1.9) or another infusion site (3.2; 95% CI, 1.3-7.7). The results were similar after
adjusting for age, gender and socioeconomic status (Table 2).

71 Discussion

72 This study of patient utilization patterns after referral for mAb reveals disparities 73 between whites and African-Americans. This occurred despite efforts to mitigate 74 barriers to utilization, including free transportation and zero out-of-pocket expenses. 75 African Americans were more likely to underutilize mAb after referral. Higher rates of 76 mAb hesitancy appear to be the main reason for underutilization. Additional factors 77 included delays due to disease severity, requiring emergency department transfer on 78 infusion date, inability to follow-up reliably as demonstrated by no-show rates, and 79 failure to be contacted.

Compared to whites, African Americans had higher odds of underutilization and mAb hesitancy as a final disposition status. This suggests that race is a strong driver of underutilization and hesitancy in the overall referred population. Hesitancy has been cited as a reason for the low uptake of mAb treatment.⁹ The higher prevalence of mAb hesitancy among African Americans in our population parallels patterns in COVID-19 vaccine hesitancy.¹⁰ A significant cause of vaccine hesitancy for African-Americans relates to concerns about safety and efficacy,¹¹ worry that treatment may be harmful

87 with a lack of trust in COVID treatment, and distrust related to unethical historical research practices among the Blacks.¹² Evidence-based approaches have been used to 88 address social, individual, and structural issues related to vaccine hesitancy.^{4,5} A similar 89 90 approach will be needed to uncover reasons for mAb hesitancy and overcome it. 91 Hesitancy to mAb may not be as entrenched as vaccines, but this treatment may also 92 have a different risk-benefit profile. Delays in care and loss to follow-up may be related 93 to economic barriers, patient perceptions of their needs, and fragmentation of care. 94 These patients may benefit if efforts to achieve equity in Covid care were expanded 95 include to mAb treatment. 96 97 As a single-site study, the generalization of these results is limited. In addition, we may 98 have missed patients who utilized services elsewhere. However, our site provided over 99 a third of infusions in the state, and our study suggests that African Americans were 100 less like to use services elsewhere. In conclusion, African Americans disproportionately 101 underutilize anti-SARS-CoV-2 monoclonal antibody treatment despite referral. 102 Hesitancy about mAb treatment may be the primary reason. There may be a similar 103 problem in the community leading to non-referral. Efforts to better understand mAb 104 hesitancy and other barriers, and proactive outreach similar to those employed for 105 Covid-19 vaccination, may be needed to mitigate barriers for underserved communities 106 and high-risk patients.

Authorship confirmation statement: All persons listed as authors meet the authorship criteria and all authors have made significant contribution in conception, design, analysis, writing and revision of the manuscript. All authors have read and approved the manuscript.

Acknowledgements: None

Disclosures: Authors do not have any conflict of interests to disclose.

Financial Support: This work was not supported by any financial grant.

Meeting Presentations: This work has not been presented at any meeting.

References

 Romano SD, Blackstock AJ, Taylor EV, et al. Trends in Racial and Ethnic Disparities in COVID-19 Hospitalizations, by Region - United States, March-December 2020.
 MMWR. Morbidity and mortality weekly report 2021;70:560-5.

2. Yaya S, Yeboah H, Charles CH, Otu A, Labonte R. Ethnic and racial disparities in COVID-19-related deaths: counting the trees, hiding the forest. BMJ global health 2020;5:e002913.

3. Nguyen LH, Joshi AD, Drew DA, et al. Racial and ethnic differences in COVID-19 vaccine hesitancy and uptake. medRxiv : the preprint server for health sciences 2021.

4. Grumbach K, Carson M, Harris OO. Achieving Racial and Ethnic Equity in COVID-19 Vaccination. JAMA health forum 2021;2:e211724.

5. Evans A, Webster J, Flores G. Partnering With the Faith-Based Community to Address Disparities in COVID-19 Vaccination Rates and Outcomes Among US Black and Latino Populations. JAMA : the journal of the American Medical Association 2021;326:609-10.

6. National Institute of Health. Anti-SARS-CoV-2 Monoclonal Antibodies. Available at: https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibodyproducts/anti-sars-cov-2-monoclonal-antibodies. Accessed 10/, 2021.

7. Jones JA, Siddiqui ZK, Callahan C, et al. Infection Prevention Considerations for a Multi-Mission Convention Center Field Hospital in Baltimore, Maryland, During the COVID-19 Pandemic. Disaster medicine and public health preparedness 2021:1-8.

8. U.S. Census Bureau; American Community Survey, 2015-2019 American Community Survey 5-Year Estimates, Table S1701. Retrieved from

https://data.census.gov/cedsci/table?q=poverty&g=0400000US24,24%248600000&tid= ACSST5Y2019.S1701; (11 October 2021).

9. Anderson TS, O'Donoghue AL, Dechen T, Mechanic O, Stevens JP. Uptake of Outpatient Monoclonal Antibody Treatments for COVID-19 in the United States: a Cross-Sectional Analysis. Journal of general internal medicine : JGIM 2021.

10. Momplaisir FM, Kuter BJ, Ghadimi F, et al. Racial/Ethnic Differences in COVID-19 Vaccine Hesitancy Among Health Care Workers in 2 Large Academic Hospitals. JAMA Network Open 2021;4:e2121931.

11. Callaghan T, Moghtaderi A, Lueck JA, et al. Correlates and Disparities of COVID-19 Vaccine Hesitancy. SSRN Electronic Journal.

12. Momplaisir F, Haynes N, Nkwihoreze H, Nelson M, Werner RM, Jemmott J.

Understanding Drivers of COVID-19 Vaccine Hesitancy Among Blacks. Clinical

infectious diseases 2021

Figure 1. Distribution of Patients Final Disposition Status Between Referral and Treatment by Race



- a. Timed out: patients past 10-day window of eligibility after symptom onset at the time of referral
- b. Hospitalized: patients hospitalized when scheduling call was made
- c. Treated elsewhere: on initial call declined appointment because treated elsewhere OR called to cancel an appointment at BCCFH because treated elsewhere
- d. Cancelled: patients called to cancel the appointment without being scheduled elsewhere
- e. Transferred to ED: Patient unstable on arrival to infusion site and transferred to ED prior to any treatment

Table 1. Patients Demographics

		African-American		p-value	
_	Total (%) N=2406	(%) N=841	White (%) N=1382		
Age (years old)	58.6 (58.0-59.2)	54.6 (53.6-55.6)	61.3 (60.5-62.1)	<0.0001	
Age Category (years old)					
<55	33.1 (31.2-35.0)	44.2 (40.8,47.5)	25.3 (23.0,27.6)	-0.0001	
>= 55	66.9 (65.0-68.8)	55.8 (52.5,59.2)	74.7 (72.4,77.0)	<0.0001	
Gender					
Female	56.9 (54.9-58.9)	66.6 (63.4-69.8)	51.7 (49.0-54.3)	<0.0001	
Male	43.1 (41.1-45.1)	33.4 (30.2-36.6)	48.3 (45.7-51.0)		
Rental Housing in Patient's Zipcode					
0-20%	27.9 (26.1-29.7)	7.8 (6.0-9.7)	40.5 (37.9-43.1)		
20 - 40%	42.5 (40.5-44.5)	40.4 (37.1-43.7)	42.8 (40.2-45.4)	<0.0001	
40%+	29.6 (27.8-31.4)	51.8 (48.4-55.2)	16.6 (14.7-18.6)		
Poverty Rate in Patient's Zipcode					
0 - 10%	64.5 (62.6-66.4)	39.2 (35.9-42.5)	78.8 (76.6-81.0)		
10 - 20%	23.0 (21.3-24.7)	31.4 (28.2-34.5)	18.0 (16.0-20.0)	<0.0001	
20+ %	12.5 (11.2-13.8)	29.5 (26.4-32.5)	3.2 (2.3-4.1)		
Baltimore City Residence	39.8 (37.8-41.7)	62.6 (59.3-65.9)	27.3 (24.9-29.6)	<0.0001	

Final Disposition Status of Referred Patients (%)	Unadjusted ¹	Adjusted ¹ *
on Status by Race		

Table 2. Comparison of Disposition Status by Race

	Overall	African American	White	OR (95%CI)	p-value	OR (95%CI)	P-value
Appropriate Utilization (ref= African American)	C vorun	, unonioun					
Treated at BCCFH (ref= African American)	69.5 (67.6- 71.3)	63.8 (60.5- 67.0)	74.0 (71.7- 76.3)	1.6 (1.3-1.9)	<0.0001	1.7 (1.4- 2.0)	<0.0001
Treated Elsewhere ^a (ref= African American)	1.7 (1.2-2.2)	0.7 (0.1-1.3)	2.2 (1.5-3.0)	3.2 (1.3-7.7)	0.0091	2.8 (1.0- 8.3)	0.0569
Under-utilization (ref=White)							
Refused Treatment (ref=White)	9.7 (8.5-10.9)	12.6 (10.3- 14.8)	8.0 (6.5-9.4)	1.7 (1.3-2.2)	0.0004	1.6 (1.2- 2.2)	0.0018
Cancelled Appointment ^b (ref=White)	4.2 (3.4-5.0)	4.2 (2.8-5.5)	3.9 (2.9-4.9)	1.1 (0.7-1.6)	0.7712	1.2 (0.8- 2.0)	0.3929
Patient "No-Show" (ref=White)	1.2 (0.7-1.6)	1.8 (0.9-2.7)	0.7 (0.2-1.1)	2.8 (1.2-6.4)	0.0165	2.4 (0.9- 6.4)	0.0849
Unable to be Reached (ref=White)	6.5 (5.5-7.5)	8.7 (6.8-10.6)	4.5 (3.4-5.6)	2.0 (1.4-2.9)	0.0001	1.9 (1.3- 2.9)	0.0014
Hospitalized ^c (ref=White)	2.1 (1.5-2.7)	2.7 (1.6-3.8)	1.7 (1.0-2.3)	1.7 (0.9-3.0)	0.0897	1.7 (0.9- 3.2)	0.1222
Timed out by Referral ^d (ref=White)	4.3 (3.5-5.1)	3.8 (2.5-5.1)	4.6 (3.5-5.7)	1.2 (0.8-1.9)	0.3921	1.1 (0.7- 1.8)	0.6626
Transferred to ED (ref=White)	1.0 (0.6-1.3)	1.8 (0.9-2.7)	0.5 (0.1-0.9)	3.5 (1.4-8.8)	0.0058	3.6 (1.4- 9.3)	0.0075
· · · · · · · · · · · · · · · · · · ·	13.8 (12.5-	16.7 (14.2-	11.9 (10.2-	1.7 (1.3-	< 0.0001	1.7 (1.3-	< 0.0001
mAb Hesitancy (ref= White)	15.2)		13.6)	2.14)		2.3)	
Overall Under-Utilization (ref=African American)	28.8 (27.0- 30.6)	35.5 (32.3- 38.7)	23.7 (21.5- 26.0)	1.8 (1.5-2.1)	<0.0001	1.8 (1.5- 2.2)	<0.0001

¹ Comparing whites and African Americans

^a Treated elsewhere: on initial call declined appointment because treated elsewhere OR called to cancel appointment at BCCFH because treated elsewhere

^b Cancelled: patients called to cancel appointment without being scheduled elsewhere

^c Hospitalized: patients hospitalized when scheduling call was made

^d Timed out by referral: patients past 10-day window of eligibility after symptom onset at time of referral

*Adjusted for Age, Gender and Poverty Level in Patient's residential zip code